facebook button Derzantinib for Patients with a Mutation in FGFR1-3
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Derzantinib for Patients with a Mutation in FGFR1-3

Sponsor: Basilea Pharmaceutica

Protocol DZB-CS-201: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations. Eligible patients will have a mutation in one of the following genes: FGFR1, FGFR2, or FGFR3.